In a report released yesterday, Brandon Folkes from Cantor Fitzgerald maintained a Buy rating on Collegium Pharmaceutical (NASDAQ: COLL), with a price target of $35. The company’s shares closed yesterday at $15.34.
Folkes commented:
“We expect upwards earnings revisions to levels not reflected in FactSet consensus to drive COLL shares higher. Valuation Summary We use a blend of DCF and EV/EBITDA to arrive at our $35 price target. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of DCF and EV/EBITDA to arrive at our $35 price target.”
According to TipRanks.com, Folkes is a 1-star analyst with an average return of -1.2% and a 38.1% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, Opiant Pharmaceuticals Inc, and Eagle Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Collegium Pharmaceutical with a $31 average price target.
See today’s analyst top recommended stocks >>
Based on Collegium Pharmaceutical’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $13.06 million. In comparison, last year the company had a GAAP net loss of $13.26 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Collegium Pharmaceutical, Inc. engages in the development and commercialization of next-generation, abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases.
